Cemiplimab significantly improved overall survival and progression-free survival compared to chemotherapy in advanced NSCLC with high PD-L1 expression. The EMPOWER-Lung 1 trial showed a median OS of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results